Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 38Rectal Neoplasms 8Colonic Neoplasms 8Neoplasm Metastasis 5Neoplasms 4Stomach Neoplasms 2Solid Tumor Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Metastatic Gastric Adenocarcinoma 1HER2 IHC3+ Advanced Colorectal Cancer 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Gastric Cancer Adenocarcinoma Metastatic 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1Carcinoma 1Bile Duct Neoplasms 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors 1Advanced Gastric Cancer 1Adenocarcinoma 1

Interventions

pembrolizumab 2Bevacizumab 2vanucizumab 1utomilumab 1trifluridine tipiracil drug combination 1selicrelumab 1mogamulizumab 1Trifluridine 1Standard of Care 1N-(6,6-dimethyl-5-((1-methylpiperidin-4-yl)carbonyl)-1,4,5,6-tetrahydropyrrolo(3,4-c)pyrazol-3-yl)-3-methylbutanamide 1Injections 1HMPL-013 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced/Metastatic Solid Tumors × Trifluridine × Clear all
NCT05405595 2026-01-07

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Adagene Inc

Phase 1/2 Recruiting
186 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡